Net survival of patients with colorectal cancer: a comparison of two periods

Štor, Zdravko; Blagus, Rok; Tropea, Alessandro; Biondi, Antonio

doi:10.1007/s13304-019-00662-z

Cited by 2 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…patients with stage IV disease at diagnosis in our study was 31%, which was higher in comparison with other countries such as Taiwan (15.9%), Korea (15.6%) and USA (19.3%), as well as stage III–IV in Spain (8.0%) ( 6 , 9 , 15 ). Cancer stage was a strong prognostic factor associated with patient survival in our study, which corresponded well with previous studies ( 1 , 3 , 4 , 9 , 13 , 15 , 16 ). Advanced disease stage was a poor prognostic factor.…”

Section: Discussionsupporting

confidence: 93%

Clinical Study of Long-Term Survival in Colorectal Cancer Patients in Thailand: A 10-Year Follow-Up

Thokanit¹,

Promchana²,

Thonkamdee³

et al. 2022

ijph

View full text Add to dashboard Cite

Background: In Thailand, data on colorectal cancer (CRC) patient characteristics and overall survival (OS) rates are limited. We aimed to describe the overall 5-year, 10-year survival and to examine factors effecting the survival outcome among patients who were diagnoses of colorectal cancer. Methods: We reviewed medical records of patients diagnosed with invasive CRC from 2007 through 2016. Demographic and clinical data were collected upon diagnosis. Kaplan-Meier method and Cox proportional hazards model to evaluate the association of overall (OS) with risk factors. Results: A total of 3,402 CRC patients (colon 59.4%, rectum 34. 5%, and rectosigmoid 6.1%) were identified. Mean (SD) and median age were 62.9 (12.7) and 63 years old (rang 14-98 years). Stages at diagnosis were I (10.1%), II (23.3), III (35.9%) and IV (30.7%). Five-year and 10-year OS of the entire cohort were 52.7% and 41.5%, respectively. Over the part 10 years, there was a trend toward improved 5-year OS in stages I, II and III. However, 3-year OS in stage IV patients remained unchanged. Confirmed poor prognostic factors included patient age ≥65 years, high grade, and advanced stage at diagnosis. Conclusion: Advanced disease was a significant prognostic factor for shorter survival. A trend toward improvement in 5-year OS in early stages over the past decade might be related to better surgical quality, improved radiation technique, and adjuvant chemotherapy. Given that patients received better systemic treatment in stage IV disease, the reason their OS was not improved should be examined.

show abstract

Section: Discussionsupporting

confidence: 93%

Clinical Study of Long-Term Survival in Colorectal Cancer Patients in Thailand: A 10-Year Follow-Up

Thokanit¹,

Promchana²,

Thonkamdee³

et al. 2022

ijph

View full text Add to dashboard Cite

show abstract

“…[ 1 ] With the development of treatment, the survival rate for patients with CRC has been obviously improved. [ 2 ] Currently, chemotherapy is still a major choice for unresectable tumors, but drug resistance limits the effectiveness of chemotherapy. [ 3 ] Therefore, it is important to develop a promising treatment of CRC.…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA LBX2‐AS1 promotes colorectal cancer progression via binding with PTBP1 and stabilizing KAT2A expression

Zhao

Wang

Lin

et al. 2022

J Biochem & Molecular Tox

View full text Add to dashboard Cite

The long noncoding RNAs (lncRNAs) have been investigated in colorectal cancer (CRC). The aim of this study is to identify the biological functions of LBX2-AS1 in CRC. Quantitative real-time polymerase chain reaction was used to examine the expression of LBX2-AS1 in CRC cells. Cell counting kit-8 and colony formation assays were performed to examine cell proliferation. Wound healing and transwell invasion assays were performed to examine the cell migration and invasion. The interaction between PTBP1 and LBX2-AS1 or KAT2A was confirmed by RNA immunoprecipitation. The KAT2A messenger RNA (mRNA) stability was probed using the transcriptional inhibitor Actinomycin D. LBX2-AS1 was significantly increased in CRC tissues and cells. Knockdown of LBX2-AS1 inhibited CRC cell proliferation, migration, and invasion. The notch signaling pathway was activated by LBX2-AS1. LBX2-AS1 enhanced the mRNA stability of the histone acetyltransferase KAT2A by interacting with RNA-binding protein PTBP1. LBX2-AS1 acted as an oncogene in CRC.

show abstract

Net survival of patients with colorectal cancer: a comparison of two periods

Cited by 2 publications

References 55 publications

Clinical Study of Long-Term Survival in Colorectal Cancer Patients in Thailand: A 10-Year Follow-Up

Clinical Study of Long-Term Survival in Colorectal Cancer Patients in Thailand: A 10-Year Follow-Up

Long noncoding RNA LBX2‐AS1 promotes colorectal cancer progression via binding with PTBP1 and stabilizing KAT2A expression

Contact Info

Product

Resources

About